IP Library Granted Patent US 7,595,332
Granted Patent B2
US 7,595,332 · App. 11/335,113 · Granted Sep 29, 2009

Amides that inhibit vanilloid receptor subtype 1 (VR1)

Assignee: Abbott Laboratories
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,595,332
App. No.
11/335,113
Granted
Sep 29, 2009
Kind
B2
Abstract

The present invention relates to compounds of formula (I) that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

Claims (28)

1. A method of treating pain wherein the pain is ameliorated by inhibiting vanilloid receptor subtype 1 (VR1) receptor in a mammal, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof

A is aryl or heteroaryl;

X is CH or N;

Y is CH or N;

L is —C(O)N(R 3 )— or —N(R 3 )C(O)—;

R 1 and R 2 are independently hydrogen, alkoxy, alkyl, aryloxy, haloalkoxy, haloalkyl, halogen, or heterocycle; and

R 3 is hydrogen or alkyl.

2. A method of treating urinary incontinence wherein the urinary incontinence is ameliorated by inhibiting vanilloid receptor subtype 1 (VR1) receptor in a mammal, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof

A is aryl or heteroaryl;

X is CH or N;

X is CH or N;

L is —C(O)N(R 3 )— or —N(R 3 )C(O)—;

R 1 and R 2 are independently hydrogen, alkoxy, alkyl, aryloxy, haloalkoxy, haloalkyl, halogen, or heterocycle; and

R 3 is hydrogen or alkyl.

3. A method of treating bladder overactivity wherein the bladder overactivity is ameliorated by inhibiting vanilloid receptor subtype 1 (VR1) receptor in a mammal, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof

A is aryl or heteroaryl;

X is CH or N;

Y is CH or N;

L is —C(O)N(R 3 )— or —N(R 3 )C(O)—;

R 1 and R 2 are independently hydrogen, alkoxy, alkyl, aryloxy, haloalkoxy, haloalkyl, halogen, or heterocycle; and

R 3 is hydrogen or alkyl.

4. A method of treating inflammatory hyperalgesia wherein the inflammatory hyperalgesia is ameliorated by inhibiting vanilloid receptor subtype 1 (VR1) receptor in a mammal, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof

A is aryl or heteroaryl;

X is CH or N;

Y is CH or N;

L is —C(O)N(R 3 )— or —N(R 3 )C(O)—;

R 1 and R 2 are independently hydrogen, alkoxy, alkyl, aryloxy, haloalkoxy, haloalkyl, halogen, or heterocycle; and

R 3 is hydrogen or alkyl.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030176/0968 →
Continuity (2)
Division 1068716400 · Oct 16, 2003
Related Publication 20060122231A1 · Jun 8, 2006